Home / Clinical trials / TB-500
Are there clinical trials for TB-500?
TB-500 has only 1 registered clinical trial, reaching Phase 2, with 0 completed. That is early-stage evidence: it is not established clinical evidence of effectiveness in humans.
Trial breakdown
By phase
| Phase 1 | 1 |
| Phase 2 | 1 |
By status
| Recruiting | 1 |
Active trials
- TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDPhase 1 / Phase 2 · Recruiting · 80 participants · Hudson Biotech · started 2026-02-05NCT07487363
Most recent registered trials
- TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDPhase 1 / Phase 2 · Recruiting · 80 participants · Hudson Biotech · started 2026-02-05NCT07487363
Frequently asked questions
Are there clinical trials for TB-500?
TB-500 has only 1 registered clinical trial, reaching Phase 2, with 0 completed. That is early-stage evidence: it is not established clinical evidence of effectiveness in humans.
Does a registered trial mean the peptide works?
No. Registration means a study was formally listed before or during the research. It says nothing about the result. A completed trial can find no benefit, and many registered studies are never published.
What is the difference between a registered trial and published evidence?
Registration records that a study exists. Publication reports what it found. This page counts registrations, which is the more complete picture of research activity, but it is not a measure of proven effectiveness.
Why do phases matter?
Phase 1 tests safety in a small group. Phase 2 looks for early signs of effect. Phase 3 tests effectiveness against a comparator in a large group, and is what regulators normally require. Phase 4 studies happen after approval. A compound with only Phase 1 trials has not been shown to work.
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine. Studies where TB-500 is registered as an intervention. Last updated 2026-09-23.